Targeting glycoproteins associated with solid cancers, a system is engineered to create novel antibody-based therapies that enhance efficacy and reduce side effects. The proprietary TegMiner™ platform facilitates the discovery of unique cancer epitopes for developing impactful antibodies for patients with unmet medical needs.